Abstract: A gel composition for treating bowel diseases comprising about 0.1 to about 2.5 wt. % of an anti-epileptic agent; about 0.8 to about 2.0% wt. % of a collagen complexed with a date palm extract of Khalas cultivar and carboxymethylcellulose; about 10 to about 50 ?g/mL of vanillic acid; about 0.1 to about 0.3 ?g of stearic acid; and water; wherein all wt. % are based on g/100 g of the gel composition. This gel composition can be topically administered to the rectum of a patient to treat one or more bowel diseases, disorders, or conditions.
Type:
Grant
Filed:
February 24, 2023
Date of Patent:
November 7, 2023
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Ezzat Khalil Ahmed, Hairul Islam Mohamed Ibrahim, Krishnaraj Thirugnanasambantham
Abstract: Compositions for topical application that effectively deliver antioxidants across the epidermis, dermis, or a combination thereof into cells and/or the bloodstream while concurrently maintaining chemical activity of the antioxidants. In certain aspects, these formulations include emulsions and balms each having a lipophilic carrier and a lipophilic antioxidant solubilized by the lipophilic carrier. Also disclosed herein are methods for making these compositions for topical application.
Abstract: A highly efficient, Z-selective ring-closing metathesis system for the formation of macrocycles using a stereoretentive, ruthenium-based catalyst supported by a dithiolate ligand is reported. This catalyst is demonstrated to be remarkably active as observed in initiation experiments showing complete catalyst initiation at ?20° C. within 10 min. Using easily accessible diene starting materials bearing a Z-olefin moiety, macrocyclization reactions generated products with significantly higher Z-selectivity in appreciably shorter reaction times, in higher yield, and with much lower catalyst loadings than in previously reported systems. Macrocyclic lactones ranging in size from twelve-membered to seventeen-membered rings are synthesized in moderate to high yields (68-79% yield) with excellent Z-selectivity (95%-99% Z).
Abstract: The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.
Type:
Grant
Filed:
April 26, 2021
Date of Patent:
November 7, 2023
Assignee:
Artax Biopharma Inc.
Inventors:
Julio Castro, Andrés Gagete Mateos, Peter J. Machin, Christopher Loren Vandeusen
Abstract: The present invention relates to a method for the synthesis of 2,5-furandicarboxylic acid, and more specifically, the present invention relates to a more efficient and economical method capable of preparing 2,5-furandicarboxylic acid having various functions with high purity and high yield, even without using a transition metal catalyst.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
October 24, 2023
Assignees:
SAMYANG CORPORATION, RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
Inventors:
Chun Rim Oh, Deuk Rak Lee, Won Jung Lee, Chi Wan Lee, Ji Eun Choi, Young Sug Kim, Jung Woon Yang, Tae Woo Lee
Abstract: Processes for preparing epoxide compounds are provided. Processes for using epoxide compounds and their industrial applications are also provided.
Type:
Grant
Filed:
June 3, 2022
Date of Patent:
October 24, 2023
Assignee:
ZSCHIMMER & SCHWARZ, INC.
Inventors:
Antonio Leyva Pérez, Judit Oliver Meseguer, Susi Hervàs Arnandis, Douglas G. Placek
Abstract: A process for preparing 5-(alkoxycarbonyl)furan-2-carboxylic acids (ACFC) by oxidizing various furcates in the presence of a catalyst containing cobalt, manganese, and bromine, and a solvent while simultaneously removing water vapor from the reaction chamber. The process can produce ACFC with high purity and low color, and in high yield.
Abstract: The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected from the group consisting of choline, N-methylaminoethanol, 2-amino-2-methylpropanol and 2-dimethylaminoethanol.
Type:
Grant
Filed:
October 31, 2019
Date of Patent:
October 17, 2023
Assignee:
APROFOL AG
Inventors:
Martin Ulmann, Gerd Wiesler, Arthur Bodenmüller, Markus Müller
Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.
Type:
Grant
Filed:
August 20, 2021
Date of Patent:
October 17, 2023
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Abstract: This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
Type:
Grant
Filed:
September 16, 2022
Date of Patent:
October 17, 2023
Assignee:
BECKLEY PSYTECH LIMITED
Inventors:
Massimo Muratore, Amir Lotfi Moghaddam, Christopher Wong
Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC) to a patient in need thereof.
Abstract: The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.
Type:
Grant
Filed:
July 14, 2022
Date of Patent:
October 10, 2023
Assignee:
Zelira Therapeutics Operations Pty Ltd
Inventors:
Harry Karelis, Mara Gordon, Stewart Smith, Stewart Washer
Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
Type:
Grant
Filed:
March 7, 2022
Date of Patent:
October 3, 2023
Assignee:
Aldeyra Therapeutics, Inc.
Inventors:
Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
Abstract: A catalyst support comprising at least 95% silicon carbide, having surface areas of ?10 m2/g and pore volumes of ?1 cc/g. A method of producing a catalyst support, the method including mixing SiC particles of 0.1-20 microns, SiO2 and carbonaceous materials to form an extrusion, under inert atmospheres, heating the extrusion at temperatures of greater than 1400° C., and removing residual carbon from the heated support under temperatures below 1000° C. A catalyst on a carrier, comprising a carrier support having at least about 95% SiC, with a silver solution impregnated thereon comprising silver oxide, ethylenediamine, oxalic acid, monoethanolamine and cesium hydroxide. A process for oxidation reactions (e.g., for the production of ethylene oxide, or oxidation reactions using propane or methane), or for endothermic reactions (e.g., dehydrogenation of paraffins, of ethyl benzene, or cracking and hydrocracking hydrocarbons).
Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
Abstract: The present invention discloses a composition containing hesperetin and synergistic hypoglycemic application thereof, and belongs to the technical field of natural active compounds. The composition of the present invention contains the hesperetin and a compound X, and the compound X is galangin or formononetin, where a mass ratio of the hesperetin to the galangin is 30:100, and a mass ratio of the hesperetin to the formononetin is 30:20. The composition of the present invention has an obvious synergistic effect of inhibiting ?-glucosidase, and the effect thereof is better than that of using the flavonoid compound alone, and may reduce a dosage of the use of drugs and occurrence of drug resistance.
Type:
Grant
Filed:
December 15, 2022
Date of Patent:
October 3, 2023
Assignee:
ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
Abstract: Disclosed in the present invention are a naphthalenesulfonamide compound, a preparation method, and an application. The naphthalenesulfonamide compound provided by the present invention can interfere with Keap1-Nrf2 binding and activate Nrf2 to relieve inflammatory damage and improve an inflammatory microenvironment, has a potential anti-inflammatory activity, and can be used for preparing an anti-inflammatory drug for inflammatory damage of various inflammation-related diseases, including chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, intestinal Inflammations, rheumatoid arthritis, etc.
Type:
Grant
Filed:
April 13, 2020
Date of Patent:
October 3, 2023
Assignee:
CHINA PHARMACEUTICAL UNIVERSITY
Inventors:
Qidong You, Zhengyu Jiang, Yuting Liu, Mengchen Lu, Hongli Shao, Jing Zhao, Xiaoli Xu, Xiaoke Guo, Lei Wang
Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
Type:
Grant
Filed:
September 7, 2022
Date of Patent:
September 26, 2023
Assignees:
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Inventors:
Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
Abstract: In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.
Type:
Grant
Filed:
April 1, 2022
Date of Patent:
September 19, 2023
Assignee:
Novartis AG
Inventors:
Gary Glick, Shomir Ghosh, William R. Roush